Snehal D. Ganjave
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Snehal D. Ganjave has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- James A. Wells
University of California, San Francisco
2 shared publications - Kevin K. Leung
Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA
2 shared publications - Trenton M. Peters-Clarke
Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA
2 shared publications - Alex Inague
Rudolf Virchow Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany
1 shared publication - Apurva Pandey
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
1 shared publication Bhat Manish
School of Biotechnology and Bioinformatics, D.Y. Patil University, CBD Belapur, Navi Mumbai, Pin-400614, Maharashtra, India
1 shared publication
Latest Publications
- Top Cited Papers
- 12 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6790) , eaec1778
Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer
Overexpression of the proto-oncogene Src is common to a wide variety of cancers. In this work, we found that Src is noncanonically translocated and inverted onto the cell surface in cancer, both in vitro and in vivo. We identified autophagolysosomal exocytosis (ALE) as a secretory mechanism prominent in cancer cell lines. Src represents the prototypical example of a family of membrane-anchored proteins that are transported by this process. Furthermore, this extracellular membrane–associated Src (eSrc) was found in primary tumors, and anti-Src antibody-based therapies mediated tumor cell killing in cell culture systems and in mouse xenograft models. Thus, intracellular N -myristoylated proteins, prototypically Src, can be topologically inverted onto the cell surface in cancer and targeted with antibody therapeutics.
- 12 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6790) , eaec1778
Top Cited PapersAutophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer
Overexpression of the proto-oncogene Src is common to a wide variety of cancers. In this work, we found that Src is noncanonically translocated and inverted onto the cell surface in cancer, both in vitro and in vivo. We identified autophagolysosomal exocytosis (ALE) as a secretory mechanism prominent in cancer cell lines. Src represents the prototypical example of a family of membrane-anchored proteins that are transported by this process. Furthermore, this extracellular membrane–associated Src (eSrc) was found in primary tumors, and anti-Src antibody-based therapies mediated tumor cell killing in cell culture systems and in mouse xenograft models. Thus, intracellular N -myristoylated proteins, prototypically Src, can be topologically inverted onto the cell surface in cancer and targeted with antibody therapeutics.
- Open Access
- 15 October 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (43) , 39912-39925
Hijacking Extracellular Targeted Protein Degrader–Drug Conjugates for Enhanced Drug Delivery
Antibody-based therapeutics encompass diverse modalities for targeting tumor cells. Among these, antibody-drug conjugates (ADCs) and extracellular targeted protein degradation (eTPD) specifically depend on efficient lysosomal trafficking for activity. A major limitation of ADCs is their reliance on antigens with efficient internalization, while eTPD approaches, although capable of trafficking diverse targets to lysosomes, lack cytotoxic potency. To address this, we developed degrader-drug conjugates (DDCs), leveraging the endocytic and recycling activities of eTPD to enhance lysosomal delivery. We utilized fast internalizers, the low-density lipoprotein receptor (LDLR) and the chemokine receptor (CXCR7), to enhance lysosomal delivery. LDLR-based degraders enabled efficient and selective degradation of diverse extracellular membrane proteins, while DDCs with cytotoxic payload enhanced cytotoxicity compared to conventional ADCs in vitro. This dual modality addresses key challenges of inadequate internalization in conventional ADCs and cytotoxic potency in current eTPD strategies. Our findings demonstrate that DDCs provide additional optionality for developing next-generation antibody therapeutics with broader utility and improved efficacy in cancer treatment.
- 15 October 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (43) , 39912-39925
Open AccessHijacking Extracellular Targeted Protein Degrader–Drug Conjugates for Enhanced Drug Delivery
Antibody-based therapeutics encompass diverse modalities for targeting tumor cells. Among these, antibody-drug conjugates (ADCs) and extracellular targeted protein degradation (eTPD) specifically depend on efficient lysosomal trafficking for activity. A major limitation of ADCs is their reliance on antigens with efficient internalization, while eTPD approaches, although capable of trafficking diverse targets to lysosomes, lack cytotoxic potency. To address this, we developed degrader-drug conjugates (DDCs), leveraging the endocytic and recycling activities of eTPD to enhance lysosomal delivery. We utilized fast internalizers, the low-density lipoprotein receptor (LDLR) and the chemokine receptor (CXCR7), to enhance lysosomal delivery. LDLR-based degraders enabled efficient and selective degradation of diverse extracellular membrane proteins, while DDCs with cytotoxic payload enhanced cytotoxicity compared to conventional ADCs in vitro. This dual modality addresses key challenges of inadequate internalization in conventional ADCs and cytotoxic potency in current eTPD strategies. Our findings demonstrate that DDCs provide additional optionality for developing next-generation antibody therapeutics with broader utility and improved efficacy in cancer treatment.
- Open Access
- 31 December 2016
- Published by International Journal Of Advanced Research in International Journal of Advanced Research
- Vol. 4 (12) , 467-474
PARTIAL PURIFICATION AND CHARACTERISATION OF L-ASPARAGINASE FROM GORDONIA SP KM067296 ISOLATED FROM LONAR LAKE (MAHARASHTRA.INDIA).
- 31 December 2016
- Published by International Journal Of Advanced Research in International Journal of Advanced Research
- Vol. 4 (12) , 467-474
Open AccessPARTIAL PURIFICATION AND CHARACTERISATION OF L-ASPARAGINASE FROM GORDONIA SP KM067296 ISOLATED FROM LONAR LAKE (MAHARASHTRA.INDIA).